Outcome of Board Meeting held on August 12, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Aspira Pathlab & Diagnostics approved the unaudited standalone and consolidated financial results for Q1 FY26 (quarter ended June 30, 2025). Standalone revenue from operations rose to Rs. 524.80 lakhs from Rs. 463.73 lakhs in Q1 FY25, a growth of about 13%. Profit after tax swung to Rs. 46.94 lakhs from a loss of Rs. 1.67 lakhs in the same quarter last year, with basic EPS of Rs. 0.41. Consolidated PAT stood at Rs. 42.15 lakhs versus Rs. 4.71 lakhs in Q1 FY25. The statutory auditor Sarda Soni Associates LLP issued an unmodified limited review opinion. The Board also appointed Dr. Alaka Keshav Deshpande (DIN: 11238406) as Additional Woman Independent Director for three years from September 27, 2025.
A return to profitability and steady revenue growth are positive signs for shareholders, though the absolute numbers remain small. The director appointment strengthens board diversity, and the clean auditor report supports confidence in the numbers.